GGrantIndex
← Leaderboards

Peter Poon-Hang Lee

Stanford University

$6,837,790
Attributed
$8,815,829
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $982.3K · FY200523
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$8,815,829 · 6

By mechanism

R01$5,373,063 · 3
U01$2,967,058 · 1
P30$296,968 · 1
K08$178,740 · 1

Top collaborators

Most similar at Stanford University

Same institution · by research overlap

Others in their field

Top investigators on “Immune

Research focus

ImmuneTumorMalignant NeoplasmsNovel StrategiesImmune ResponseCellsResearch PersonnelCancer TherapyInsightCytokineImmune SystemFlow CytometryLeadMalignant Breast NeoplasmT-LymphocyteBaseHistologyHelper-Inducer T-LymphocyteImmunotherapyData AnalysesData SetCollaborationsBiologicalCd4 Positive T Lymphocytes

Grant awards (29)

Experimental-Computational Synthesis of Altered Immune Signaling in Breast Cancer$183,872
U01 · FY2023 · CA · contact PI
Experimental-Computational Synthesis of Altered Immune Signaling in Breast Cancer$612,300
U01 · FY2022 · CA · contact PI
Cancer Immunotherapeutics$60,976
P30 · FY2022 · CA · contact PI
Experimental-Computational Synthesis of Altered Immune Signaling in Breast Cancer$921,294
U01 · FY2021 · CA · contact PI
Cancer Immunotherapeutics$60,976
P30 · FY2021 · CA · contact PI
Experimental-Computational Synthesis of Altered Immune Signaling in Breast Cancer$624,796
U01 · FY2020 · CA · contact PI
Cancer Immunotherapeutics$68,118
P30 · FY2020 · CA · contact PI
Experimental-Computational Synthesis of Altered Immune Signaling in Breast Cancer$624,796
U01 · FY2019 · CA · contact PI
Cancer Immunotherapeutics$59,314
P30 · FY2019 · CA · contact PI
Cancer Immunotherapeutics$45,501
P30 · FY2018 · CA · contact PI
Cancer Immunotherapeutics$2,083
P30 · FY2018 · CA · contact PI
Interplay Between Cancer and Immune Cells on Targeted Therapy$341,262
R01 · FY2012 · CA · contact PI
Interplay Between Cancer and Immune Cells on Targeted Therapy$450,198
R01 · FY2011 · CA · contact PI
Immune Profile Analysis of Tumor-Draining Lymph Nodes in Breast Cancer$252,440
R01 · FY2011 · CA · contact PI
Immune Profile Analysis of Tumor-Draining Lymph Nodes in Breast Cancer$116,079
R01 · FY2011 · CA · contact PI
Interplay Between Cancer and Immune Cells on Targeted Therapy$444,515
R01 · FY2010 · CA · contact PI
Immune Profile Analysis of Tumor-Draining Lymph Nodes in Breast Cancer$364,799
R01 · FY2010 · CA · contact PI
Interplay Between Cancer and Immune Cells on Targeted Therapy$437,707
R01 · FY2009 · CA · contact PI
Immune Profile Analysis of Tumor-Draining Lymph Nodes in Breast Cancer$358,017
R01 · FY2009 · CA · contact PI
Interplay Between Cancer and Immune Cells on Targeted Therapy$435,170
R01 · FY2008 · CA · contact PI
Immune Profile Analysis of Tumor-Draining Lymph Nodes in Breast Cancer$347,963
R01 · FY2008 · CA · contact PI
Immune Profile Analysis of Tumor-Draining Lymph Nodes in Breast Cancer$358,886
R01 · FY2007 · CA · contact PI
Characterization of Tumor Specific T Cells in Melanoma$303,175
R01 · FY2005 · CA
Characterization of Tumor Specific T Cells in Melanoma$301,936
R01 · FY2004 · CA
Characterization of Tumor Specific T Cells in Melanoma$300,732
R01 · FY2003 · CA
Characterization of Tumor Specific T Cells in Melanoma$299,564
R01 · FY2002 · CA
Characterization of Tumor Specific T Cells in Melanoma$260,620
R01 · FY2001 · CA
ENDOGENOUS T CELL RESPONSES TO MELANOMA$89,370
K08 · FY2001 · CA
ENDOGENOUS T CELL RESPONSES TO MELANOMA$89,370
K08 · FY2000 · CA